C
PRME icon

Covestor’s Prime Medicine PRME Stock Holding History

Covestor’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
105
+74
+239% +$246 ﹤0.01% 2769
2026
Q1 		$0 Hold
31
– – ﹤0.01% 2671
2025
Q4 		$0 Hold
31
– – ﹤0.01% 2642
2025
Q3 		$0 Hold
31
– – ﹤0.01% 2660
2025
Q2 		$0 Sell
31
-2
-6% -$3 ﹤0.01% 2638
2025
Q1 		$0 Buy
33
+19
+136% +$48 ﹤0.01% 2618
2024
Q4 		$0 Buy
14
+1
+8% +$4 ﹤0.01% 2626
2024
Q3 		$0 Sell
13
-1
-7% -$5 ﹤0.01% 2635
2024
Q2 		$0 Hold
14
– – ﹤0.01% 2638
2024
Q1 		$0 Sell
14
-1
-7% -$8 ﹤0.01% 2625
2023
Q4 		$0 Buy
15
+7
+88% +$54 ﹤0.01% 2583
2023
Q3 		$0 Sell
8
-1
-11% -$13 ﹤0.01% 2576
2023
Q2 		$0 Hold
9
– – ﹤0.01% 2527
2023
Q1 		$0 Buy
+9
New +$147 ﹤0.01% 2453

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Covestor's PRME Position: Q2 2026 in Review

Covestor increased its Prime Medicine (PRME) stake by 239% in Q2 2026, buying an estimated $246 and bringing the position to 105 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2769.

Covestor first reported a position in PRME in Q1 2023 and has held it in 14 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Covestor held 105 shares of Prime Medicine worth $0 as of Q2 2026.
  • Covestor bought 74 Prime Medicine shares in Q2 2026, an estimated $246.
  • Prime Medicine made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2769 holding.
  • Covestor first reported a position in Prime Medicine in Q1 2023 and has held it in 14 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.